LZLiya Zhou

Liya Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liya Zhou has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024–2025 National Multicenter Cross‐Sectional Study

    by Zhihao Yin, Zhiqiang Song, Xinlu Ren, Ye Chen, Bin Lv, Hong Lu, Yong Xie, Yiling Li, Xuehong Wang, Chunhui Lan, et al.

    Background: This study aimed to investigate the current knowledge, attitudes, and practices of Chinese physicians regarding the management of Helicobacter pylori infection through a large‐scale national survey. Materials and Methods: This national, multicenter cross‐sectional survey was conducted from October 2024 to May 2025 among physicians from over 2200 medical institutions across 31 provinces using an online questionnaire. The survey comprised four dimensions: basic information, knowledge, attitudes, and practices. Results were compared with the Sixth Chinese National Consensus Report on the Management of H. pylori infection and the Maastricht VI/Florence guidelines. Further, subgroup analyzes were conducted. Results: A total of 6030 valid responses were included. Knowledge : Only 27.5% of participants correctly estimated the H. pylori infection rate as 40%–50%, and 13.5% accurately understood the reinfection rate as 2%. Attitude : Overall, 93.4% of participants reported familiarity with Chinese H. pylori guidelines and consensus statements, and 84.1% supported replacing proton pump inhibitors with potassium‐competitive acid blockers. Practice : Gaps were observed in recognizing indications for H. pylori eradication, including unexplained iron deficiency anemia (43.9%), primary immune thrombocytopenia (39.6%), vitamin B12 deficiency (32.3%), and H. pylori infection without countervailing factors (36.8%). The bismuth‐based quadruple regimen was the most commonly selected first‐line treatment (86.7%); however, 74.5% still selected the amoxicillin + clarithromycin combination, despite the high resistance rate associated with clarithromycin. The dual regimen is gradually gaining acceptance (53.9%). Subgroup analyzes : Greater adherence to guideline recommendations was observed among physicians from higher‐level medical institutions, gastroenterologists, those with more years of practice, higher professional titles, and educational levels, as well as those practicing in economically developed regions. Conclusion: Chinese physicians generally follow guideline‐recommended core practices for the diagnosis and treatment of H. pylori . However, notable gaps persist in understanding reinfection rates, identifying appropriate eradication indications, and selecting optimal treatment regimens. Therefore, strengthened educational interventions are warranted.

  • Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real‐World Practice

    by Duc Trong Quach, Jyh‐Ming Liou, Javier P. Gisbert, Wai Keung Leung, Steven F. Moss, Carlo A. Fallone, Peter Katelaris, Christian Schulz, Violet Kayamba, Liya Zhou, et al.

    Background: Despite increasingly refined diagnostic strategies and regularly updated treatment guidelines, real‐world outcomes of Helicobacter pylori management remain variable. Antimicrobial resistance alone does not fully explain these discrepancies, suggesting important challenges in the implementation of evidence‐based care. Aims: To identify recurring implementation‐related challenges across the Helicobacter pylori care pathway and highlight priorities for improving real‐world management. Methods: This expert‐informed review integrated relevant literature, international guideline documents, and structured international expert prioritisation. An initial list of implementation‐related pitfalls was developed through literature review, clinical experience, and discussions among the coordinating authors and selected co‐authors. Twenty‐six experts from five continents participated in a structured consultation process and rated predefined pitfalls using a 5‐point Likert scale. Median scores were used for relative prioritisation. Results: Treatment selection and patient management emerged as the domains most consistently prioritised by participating experts. High‐impact pitfalls included empirical triple therapy in high‐resistance settings, inadequate patient counselling, and empirical retreatment without escalation. Additional challenges were identified across diagnostic, treatment, and follow‐up domains, highlighting persistent implementation‐related barriers throughout the care pathway. Conclusions: Recurring implementation‐related challenges remain important barriers to optimal Helicobacter pylori management. Structured expert prioritisation highlights potential targets for improvement and supports further research and implementation‐focused strategies to improve delivery of care.


  • Open Access

    A Review on the Progress and Strategies of Helicobacter pylori Eradication Therapy for Patients With Penicillin Allergy

    by Yuxin Zhang, Baojun Suo, Xueli Tian, Cailing Li, Xinlu Ren, Kai Zhou, Changmin Mi, Yuxin Wang, Lingling Ma, Liya Zhou, et al.

    Background: Helicobacter pylori (H. pylori) eradication in penicillin‐allergic patients poses a challenge. The currently recommended regimens are inadequate for clinical eradication therapy. Recent years have seen reports of new drugs, regimens, and study evidence in this field; yet comprehensive review articles on the treatment of H. pylori infection in penicillin‐allergic patients are scarce. Methods: A literature search of PubMed, Web of Science, Embase, China National Knowledge Infrastructure, the China Science and Technology Journal Database, and the Wanfang Database up to January 10, 2026, was conducted with the search strategy (“ Helicobacter pylori” OR “H. pylori ”) AND (“treatment” OR “therapy”) AND (“penicillin” OR “beta‐lactam”) AND (“allergy”, “allergic” OR “anaphylaxis”) for both English and Chinese language publications Results: The final literature review included 132 treatment groups from 56 studies in nine different countries or regions, with a total of 5542 patients included in the analyses. The overall eradication rates of triple regimens were unsatisfactory (72.9%, 95% CI 70.7%–75.2%). The classic quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is commonly recommended due to its relatively satisfactory efficacy and sufficient research evidence (81.4%, 95% CI 78.6%–84.2%). The mean eradication rate for other regimens containing new drugs such as minocycline, cefuroxime, sitafloxacin, vonoprazan, and rifabutin is well (> 80%). Conclusion: The classical bismuth quadruple therapy used to be the most commonly used regimen. The overall eradication efficacy of triple therapies is unacceptable. Although new drugs and regimens have emerged, their efficacy needs confirmation through more high‐quality, large‐scale clinical studies to identify the optimal eradication therapy regimen. Individualized treatment, particularly therapies tailored based on the results of genetic antibiotic resistance testing, represents an important direction for future research.


  • Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial

    by Zhiqiang Song, Xiuli Zuo, Zhenyu Zhang, Xuehong Wang, Ya Lin, Yueyue Li, Xiaojun Xu, Yun Huang, Qiuyan Wang, Yanyan Shi, et al.

    Background: The optimal duration for vonoprazan and amoxicillin dual therapy (VA‐DT) remains unclear, and studies on gastric acid suppression of vonoprazan during eradication are still lacking. Objective: This study conducted a multicenter, randomized controlled trial to compare the eradication efficacy between 10 and 14‐day VA‐DT, and to identify the dynamic changes of gastric pH during treatment. Methods: This study included 418 naïve adult patients with Helicobacter pylori infection, who were randomly divided into 10 or 14‐day VA‐DT groups (vonoprazan 20 mg twice daily and amoxicillin 1000 mg thrice daily). 13 C‐urea breath tests were conducted at 4–8 weeks after eradication to evaluate the success of treatment. 24‐h intragastric pH was monitored in 22 patients. Results: Ten and 14‐day VA‐DT demonstrated eradication rates of 83.3% vs. 88.0% (rate difference: −4.8%, 95% confidence interval: −11.6% to −2.0%) in intention‐to‐treat analysis, 87.9% vs. 93.9% (−6.0%, −11.9% to −0.3%) in modified intention‐to‐treat analysis, and 89.1% vs. 95.3% (−6.1%, −11.8% to −0.7%) in per‐protocol analysis, respectively. Vonoprazan showed excellent gastric acid suppression during eradication, with the time percentages of pH > 6 at 75.3% and 97.2% and the median pH levels at 7.4 and 7.8 on the 1st and 7th days, respectively. Furthermore, gastric pH exceeded 6 approximately 4–5 h after the first dose and remained stable at 7–9 thereafter. Conclusion: The noninferiority of eradication efficacy between 10‐ and 14‐day VA‐DT in the first‐line treatment was not established, indicating that 10‐day therapy cannot be used as a substitute for 14‐day therapy. Vonoprazan exerted excellent gastric acid suppression during eradication. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2200057625


  • Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial

    by Baojun Suo, Xinlu Ren, Cailing Li, Yanyan Shi, Xueli Tian, Kai Zhou, Liya Zhou, Zhiqiang Song

    Background: Tailored therapy based on genetic testing of fecal samples is a promising method for Helicobacter pylori eradication, but relevant research is still lacking, and the effectiveness remains unclear. Objective: This study conducted a randomized controlled trial to evaluate the efficacy, safety, and compliance of triple plus bismuth therapy (TBT) guided by clarithromycin and levofloxacin genotypic resistances and CYP2C19 polymorphisms from stool samples. A preliminary health economics analysis was also conducted. Design: Six hundred and sixteen treatment‐naïve patients were randomly divided into tailored (individualized drug selection based on genetic testing for 7 or 14 days) and empiric (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all twice daily for 14 days) TBT groups. Safety and compliance were assessed within 1–3 days after eradication. 13 C‐urea breath test was performed within 4–8 weeks after eradication to evaluate the therapeutic outcome. Results: The eradication rates of the tailored TBT group were non‐inferior to those of the empiric TBT group [intention‐to‐treat analysis 87.7% vs. 80.8%, rate difference 6.8% (95% confidence interval 0.8%–12.9%); modified intention‐to‐treat analysis 93.4% vs. 86.8%, rate difference 6.7% (95% confidence interval 1.5%–11.9%); per‐protocol analysis 95.7% vs. 88.7%, rate difference 7.0% (95% confidence interval 2.2%–11.8%)]. The tailored TBT group achieved satisfactory efficacies (acceptable in intention‐to‐treat and excellent in per‐protocol analyses). Safety and compliance were similar between the two groups. The average cost of each successful eradication case in the tailored TBT group is lower than that in the empiric TBT group. Conclusion: The tailored TBT guided by antibiotic genotypic resistances and CYP2C19 polymorphisms detected from fecal specimens achieved satisfactory efficacy, safety, and compliance in the first‐line Helicobacter pylori eradication with less expenses (ChiCTR2300068620). Trial Registration: Chinese Clinical Trials Registration: ChiCTR2300068620


  • Open Access

    Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment of Helicobacter pylori infection: a systematic review and meta-analysis

    by Cailing Li, Kai Zhou, Baojun Suo, Yanyan Shi, Guangjie Ping, Liya Zhou, Zhiqiang Song

    Background: Tailored therapy is crucial for reducing the irrational use of antibiotics and enhancing Helicobacter pylori ( H. pylori ) eradication rates. Detection of antibiotic resistance gene mutations offers a rapid, accurate, and simple approach for tailored therapy, facilitating its widespread clinical implementation. However, the efficacy, safety, adherence, and cost-effectiveness of tailored therapy guided by genotypic resistance from gastric mucosa samples for first-line H. pylori treatment remain unclear. Objectives: This study aims to clarify the efficacy, safety, patient compliance, and cost-effectiveness of genotypic resistance-guided tailored therapy for first-line H. pylori treatment. Design: A systematic review and meta-analysis following the PRISMA 2020 guidelines. Data sources and methods: The literature was searched in PubMed, Web of Science, and Wanfang databases under the keywords “ Helicobacter pylori ,” “tailored therapy,” and “genotypic resistance” before March 1, 2025. Two investigators independently performed data extraction and literature quality assessment. Single-arm meta-analysis was performed using the Meta package of the R program to summarize the efficacy, safety, and compliance of tailored therapy, and classical meta-analysis was performed using Review Manager to compare tailored therapy with empirical treatment. Dichotomous outcomes were summarized using relative risks with 95% confidence intervals. Results: Of 1524 retrieved articles, 29 (including 4895 patients) met inclusion criteria for single-arm meta-analysis, and 17 (including 6208 patients) were included in the classical meta-analysis by further excluding studies that did not use empirical treatment as control. The single-arm meta-analysis demonstrated satisfactory efficacy of tailored therapy in first-line H. pylori treatment (intention-to-treat analysis: 84.4%, per-protocol analysis: 91.7%), with good safety (adverse event rate: 26.6%) and adherence (98.0%). Tailored therapy showed a higher overall eradication rate than empirical treatment. Subgroup analysis indicated that tailored therapy outperformed standard triple therapy and was comparable to bismuth quadruple therapy and concomitant therapy in terms of efficacy, with similar safety and adherence across groups. Health economic evidence was limited, but most studies suggested that tailored therapy incurred higher costs per successful eradication than empirical treatment. Conclusion: Tailored therapy guided by genotypic resistance detected from gastric mucosa samples demonstrates satisfactory eradication efficacy in first-line H. pylori treatment, superior to standard triple therapy and comparable to bismuth quadruple therapy, with comparable safety and adherence. Current evidence supports bismuth quadruple therapy as the optimal first-line treatment for H. pylori infection. Considering factors such as cost-effectiveness and technical accessibility, it is more appropriate to implement tailored therapy in countries and regions with adequate resources and capabilities. Trial registration: This study was not registered in PROSPERO, and future systematic reviews and meta-analyses will be registered in advance.


  • Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta‐analysis

    by Xinlu Ren, Yanyan Shi, Baojun Suo, Xingyu Yao, Haoping Lu, Cailing Li, Yuxin Zhang, Liya Zhou, Xueli Tian, Zhiqiang Song

    Background: Empiric therapy for Helicobacter pylori infection results in significantly increased antibiotic resistance and decreased eradication efficacy. The genotypic testing of clarithromycin resistance from stool specimens is a promising method for individualized diagnosis and treatment. This study aimed to determine the status of research and application on this method through a systematic review and meta‐analysis.Methods: PubMed, Embase, MEDLINE, and WAN FANG database were searched for relevant literature. The quality of included diagnostic articles was evaluated using the quality Assessment of Diagnostic Accuracy Studies‐2 tool. A bivariate random‐effect model was conducted to calculate the diagnostic accuracy of genotypic testing of clarithromycin resistance.Results: A total of 16 diagnostic‐related were included and analyzed after exclusions. The pooled sensitivity and specificity of diagnostic meta‐analysis were 0.93 (95% confidence interval [CI]: 0.90–0.96) and 0.98 (95% CI: 0.93–1.00), respectively. The area under the curve (AUC) of the summary receiver operating characteristic was 0.97 (95% CI: 0.95–0.98). The genotypic testing in stool samples had heterogeneous sensitivity (Q = 37.82, p < .01, I2 = 37.82) and specificity (Q = 60.34, p < .01, I2 = 93.72) in detecting clarithromycin resistance. Purification method, stool sample weight, real‐time PCR, and antimicrobial susceptibility testing as reference accounted for the heterogeneity of pooled sensitivity, while patient age, purification method, stool sample weight, and real‐time PCR for the heterogeneity of pooled specificity.Conclusion: The genotypic testing of clarithromycin resistance from stool specimens is an accurate, convenient, noninvasive, and rapid detection technology, providing a definitive diagnosis of clarithromycin resistance and guiding the rational antibiotic selection.


  • New regimens as first‐line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial

    by Yuxin Zhang, Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Xingyu Yao, Cailing Li, Xinlu Ren, Liya Zhou, Zhiqiang Song

    Background: Helicobacter pylori eradication in penicillin‐allergic patients is challenging. The effective regimen is lacking in areas with high antibiotic resistance and tetracycline unavailable. Minocycline, cefuroxime, and full‐dose metronidazole are promising drugs.Aims: To compare the eradication rate, safety, and compliance among three new bismuth quadruple therapies for first‐line H. pylori eradication in penicillin‐allergic patients.Methods: This randomized trial was conducted on 450 naive patients with H. pylori infection and penicillin allergy. The 14‐day minocycline‐metronidazole‐containing (minocycline 100 mg twice daily and metronidazole 400 mg four times/day), minocycline‐cefuroxime‐containing (minocycline 100 mg twice daily and cefuroxime 500 mg twice daily), and cefuroxime‐metronidazole‐containing (cefuroxime 500 mg twice daily and metronidazole 400 mg four times/day) bismuth quadruple therapies were randomly assigned to the participants. Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed 4–8 weeks after eradication to evaluate outcome.Results: The differences of eradication rates in either intention‐to‐treat (84.0%, 82.7%, and 23 82.0%, p = .896) or per‐protocol (91.7%, 90.9%, and 88.2%, p = .599) analysis among minocycline‐metronidazole, minocycline‐cefuroxime, and cefuroxime‐metronidazole‐containing bismuth quadruple therapies were statistically insignificant. The incidence of adverse events (35.1%, 22.6%, and 28.9%) and compliance (90.5%, 91.8%, and 91.9%) were similar. Taste distortion, nausea, and anorexia were more common in metronidazole‐containing regimens, and dizziness was more common in minocycline‐containing regimens. The allergy was rare (~3%).Conclusions: The efficacies of three bismuth quadruple therapies containing minocycline, cefuroxime, and full‐dose metronidazole (pairwise) for first‐line H. pylori eradication in penicillin‐allergic patients were similarly satisfactory with relatively good safety and compliance. The study was registered in the Chinese Clinical Trials Registration (ChiCTR1900023702).